PEComas: what are the treatment options? Literature review and personal experience
- Авторлар: Protsenko S.A.1, Degtiareva E.A1, Teletaeva G.M1, Levchenko E.V1, Levchenko N.E1, Mishchenko A.V1, Burovik I.A1, Artemyeva A.S1, Imyanitov E.N1, Semenova A.I1, Novik A.V1, Latipova D.K.1
-
Мекемелер:
- N.N. Petrov National Medical Research Center of Oncology
- Шығарылым: Том 26, № 7 (2019)
- Беттер: 102-107
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312215
- DOI: https://doi.org/10.18565/pharmateca.2019.7.102-107
- ID: 312215
Дәйексөз келтіру
Аннотация
Негізгі сөздер
Толық мәтін
Авторлар туралы
Svetlana Protsenko
N.N. Petrov National Medical Research Center of Oncology
Email: s.protsenko@list.ru
MD, Professor, Head of the Department of Chemotherapy and Innovative Technologies 68, Leningradskaya Street, Pesochny settlement, St. Petersburg 197758, Russian Federation
E. Degtiareva
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
G. Teletaeva
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
E. Levchenko
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
N. Levchenko
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
A. Mishchenko
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
I. Burovik
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
A. Artemyeva
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
E. Imyanitov
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
A. Semenova
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
A. Novik
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
D. Latipova
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
Әдебиет тізімі
- Armah H.B., Parwani A.V. Perivascular Epithelioid Cell Tumor Arch Pathol Lab Med. 2009;133(4):648-54. doi: 10.1043/15432165-133.4.648.
- Thway K., Fisher C. PEComa: morphology and genetics of a complex tumor family Ann Diagn Pathol. 2015;19(5):359-68. Doi: 10.1016/j. anndiagpath.2015.06.003.
- Fletcher C.D., Unni K.K., Mertens F. World health organization classification of tumors: pathology and genetics of tumors of soft tissue and bone. Lyon: IARC Press, 2002. Р 12-224.
- Shankar V PEComa - general. PathologyOutlines. com website. http://www.pathologyoutlines.com/topic/softtissuepecgeneral.html. 2019.
- Starbuck K.D., Drake R.D., Budd G.T., et al. Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature. Anticancer Res. 2016;36(11):6161-64.
- Schoolmeester J.K., Dao L.N., Soslow R.A. TFE3 Translocation Associated Perivascular epithelial cell tumor (PEComa) of the Gynecologic Tract: Morphology, Immunophenotype, Differential Diagnosis. Am J Surg Pathol. 2015;39(3):394-404. doi: 10.1097/PAS.0000000000000349.
- Zhang S., Chen F, Huang X., et al. Perivascular epithelial cell tumor (PEComa) of the pancreas: A case report and review of literature. Medicine (Baltimore). 2017;96(22):e7050. doi: 10.1097/MD.0000000000007050.
- Sadeghi S., Krigman H., Maluf H. Perivascular epithelioid clear cell tumor of the common bile duct. Am J Surg Pathol. 2004;28(8):1107-10.
- Doyle L.A., Hornick J.L., Fletcher C.D. PEComa of the gastrointestinal tract: clinicopathologic study of 35 cases with evaluation of prognostic parameters. Am J Surg Pathol. 2013;37(12):1769-82. doi: 10.1097/PAS.0b013e31829caab3.
- Kwazneski II D., Merrill M., Young J., et al. Angiomyolipoma and Malignant PEComa: Discussion of Two Rare Adrenal Tumors. Case Rep Oncol Med. 2016;2016:5204092. doi: 10.1155/2016/5204092.
- Eken A., Saglican Y Primary perivascular epithelioid cell tumour (PEComa) of the prostate. Can Urol Assoc J. 2014;8(5-6):E455-57. doi: 10.5489/cuaj.1752.
- Schoolmeester J.K., Howitt B.E., Hirsch M.S., et al. Perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: clinicopathologic and immunohistochemical characterization of 16 cases. Am J Surg Pathol. 2014;38(2):176-88. doi: 10.1097/PAS.0000000000000133.
- Okamoto K., Okada Y., Ohno K., et al. A rare case of perivascular epithelioid cell tumor (PEComa) of the greater omentum. World J Surg Oncol. 2018;16(1):113. doi: 10.1186/s12957-018-1407-5.
- Llamas-Velasco M., Requena L., Mentzel T. Cutaneous perivascular epithelioid cell tumors: A review on an infrequent neoplasm. World J Methodol. 2016;6(1):87-92. doi: 10.5662/wjm.v6.i1.87.
- Lao I.W., Yu L., Wang J. Malignant perivascular epithelioid cell tumor (PEComa) of the femur: a case report and literature review. Diagn Pathol. 2015;10:54. doi: 10.1186/s13000-015-0292-2.
- Paliogiannis P, Palmieri G., Tanda F, et al. Perivascular Epithelioid Cell Tumors (PEComas) of the Orbit. J Pathol Transl Med. 2017;51(1):7-8. doi: 10.4132/jptm.2016.10.26.
- Huilin Niu, Wang F.W., Zhang P.J., et al. Cardiac Epithelioid PEComa: Report of Two Cases and Review of the Literature. Case Reports in Oncological Medicine. 2012. doi: 10.1155/2012/521678.
- Wejman J., Nowak K., Gielniewska L., et al. PEComa of the mesentery coexisting with colon cancer: a case report. Diagn Pathol. 2015;10:31. doi: 10.1186/s13000-015-0265-5.
- Нечушкина И.В. Пекомы. Онкопедиатрия. 2016;3(4):267-76.
- Unluoglu S., Bayol U., Korkmaz N., et al. Perivascular epithelioid cell tumor of the ileum presenting as diverticulitis. Case Rep Pathol. 2012;2012:476941. doi: 10.1155/2012/476941.
- Osei D.A., Alvandi F., Brooks J.S., et al. PEComa of the Upper Extremity: A Unique Case and Description of an Initial Response to Neoadjuvant Chemotherapy. Sarcoma. 2007;2007:53056.
- Bergamo F., Maruzzo M., Basso U., et al. Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa). World J Surg Oncol. 2014;12:46.
- Bleeker J.S., Quevedo J.F., Folpe A.L. "Malignant" Perivascular Epithelioid Cell Neoplasm: Risk Stratification and Treatment Strategies. Sarcoma. 2012;2012:541626. doi: 10.1155/2012/541626
- Hindi N., Sanfilippo R., Stacchiotti S., et al. 1450P -Systemic therapy in perivascular epithelioid cell tumors (PEComa). Ann Oncol. 2014;25(4): iv506-iv506.
- Bissler J.J., McCormack F.X., Young L.R., et al. Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis. N Engl J Med. 2008;358(2):140-51. doi: 10.1056/NEJMoa063564.
- Benson C., Vitfell-Rasmussen J., Maruzzo M., et al. A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience. Anticancer Res. 2014;34(7): 3663-68.
- Wagner A.J., Malinowska-Kolodziej I., Morgan J.A., et al. Clinical activity of mTOR inhibition with siroiimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORCI in tumors. J Clin Oncol. 2010;28(5):835-40. doi: 10.1200/JCO.2009.25.2981
- RAPAMUNE (sirolimus) tablets label - FDA. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021083s059.021110s076lbl.pdf.
- Italiano А, Delcambre C., Hostein I., et al. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol. 2010;21(5):1135-37. doi: 10.1093/annonc/mdq044.
- Flechter E., Zohar Y, Guralnik L., et al. Long-lasting stable disease with mTOR inhibitor treatment in a patient with a perivascular epithelioid cell tumor: A case report and literature review. Oncol Lett. 2016;12(6):4739-43. doi: 10.3892/ol.2016.5231.
- Gennatas C., Michalaki V., Kairi P.V., et al. Successful treatment with the mTOR inhibitor everolimus in a patient with Perivascular epithelioid cell tumor. World J Surg Oncol. 2012;10:181. doi: 10.1186/1477-7819-10-181.
- Mehren M., Kane J.M. Ill, Benjamin R.S., et al. Soft Tissue Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J National Comprehensive Cancer Network: JNCCN. 2018;16(5):536-63.
- Casali P.G., Abecassis N., Bauer S., et al. On behalf of the ESMO Guidelines Committee and EURACAN. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(4): iv51-iv67.
- Gao F., Huang C., Zhang Y, et al. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa. Cancer Biol Ther. 2016;17(6):595-98. doi: 10.1080/15384047.2016.1167290.
- Scheppach W., Reissmann N., Sprinz T, et al. PEComa of the colon resistant to sirolimus but responsive to doxorubicin/ifosfamide. World J Gastroenterol. 2013;19(10):1657-60. doi: 10.3748/wjg.v19.i10.1657.
- Anti-PD-1 therapy with nivolumab in the treatment of metastatic malignant PEComa. The Sarcoma J. 2018;2(1):7-9.
- Le P., Garg A., Brandao G., et al. Hormonal manipulation with letrozole in the treatment of metastatic malignant pecoma. Curr Oncol. 2014;21(3):e518-20. Doi: 10.3 747/co.21.1849.
- Lattanzi M., Deng F.M., Chiriboga L.A., et al. Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy. J Immunother Cancer. 2018;6(1):97. doi: 10.1186/s40425-018-0415-x.